安杰思收盘下跌1.48%，滚动市盈率21.42倍，总市值63.18亿元

Group 1 - The core viewpoint of the articles highlights the performance and market position of Anjiasi Medical Technology Co., Ltd. in the medical device industry, particularly focusing on its financial metrics and stock performance [1][2] - As of August 8, Anjiasi's closing stock price was 78.02 yuan, reflecting a decrease of 1.48%, with a rolling price-to-earnings (PE) ratio of 21.42 times and a total market capitalization of 6.318 billion yuan [1] - The average PE ratio for the medical device industry is 55.70 times, with a median of 39.08 times, positioning Anjiasi at the 46th rank within the industry [1][2] Group 2 - Anjiasi's main business involves the research, development, production, and sales of minimally invasive diagnostic and therapeutic instruments, with key products including GI, EMR/ESD, and ERCP diagnostic series [1] - The latest financial report for the first half of 2025 indicates that Anjiasi achieved an operating revenue of 302 million yuan, representing a year-on-year increase of 14.56%, and a net profit of 126 million yuan, also reflecting a year-on-year increase of 1.26%, with a gross profit margin of 70.21% [1]